ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to bl... ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 5.83 | 6.15 | 5.66 | 11493 | 5.94738541 | CS |
| 4 | 0.36 | 6.58135283364 | 5.47 | 6.15 | 5.42 | 11819 | 5.78847662 | CS |
| 12 | 1.26 | 27.5711159737 | 4.57 | 6.64 | 4.51 | 368622 | 6.00865496 | CS |
| 26 | -1.11 | -15.9942363112 | 6.94 | 7.6 | 3.94 | 191071 | 6.04626837 | CS |
| 52 | -9.43 | -61.7955439056 | 15.26 | 17.96 | 3.94 | 130453 | 6.51236773 | CS |
| 156 | -9.43 | -61.7955439056 | 15.26 | 17.96 | 3.94 | 130453 | 6.51236773 | CS |
| 260 | -9.43 | -61.7955439056 | 15.26 | 17.96 | 3.94 | 130453 | 6.51236773 | CS |
Truthsocial
16分前
TightCoil
20分前
art2426
21分前
rich2
23分前
art2426
30分前
bigstocksnbonds
30分前
tombe
31分前
Sambizzi
32分前
PEMBROKE1
34分前
TMaga
39分前
Latenightmike57
45分前
PEMBROKE1
45分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。